RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
REGENXBIO Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$7.15+0.23 (+3.25%)
Close on Oct 19, 2026
- Market cap
- $379.06M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.58 (−39.05%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
REGENXBIO Inc. grew revenue 12.0% to $174.48M over the twelve months to Jun 30, 2026. Free cash flow was -$249.67M.
Revenue
$174.48M
+12.0% vs. a year earlier
Operating income
-$164.15M
TTM Q2 2026
Free cash flow
-$249.67M
TTM Q2 2026
EPS, diluted
-$3.79
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $379.06M
- P/E ratio
- –
- Price to sales
- 2.17
- Price to book
- 5.28
- Dividend yield
- –
- Free cash flow yield
- -65.86%
Fundamentals
- Revenue
- $174.48M
- Net income
- -$196.43M
- EPS, diluted
- -$3.79
- Free cash flow
- -$249.67M
- Book value per share
- $1.35
- Diluted shares
- 53M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$174.48M+12.0% YoY
Gross profit
–
Operating income
-$164.15M
Net income
-$196.43M
EPS, diluted
-$3.79
Free cash flow
-$249.67M
Reported periodTrailing twelve months